Skip to content
Menu

Xencor, Inc. XNCR

Full chart Compare
Set alert

Price alert · XNCR

All alert types
37.09 USD -1.04 (-2.73%)

Regular-session close

37.09 0.00 0.00%

After hours · Nov 13, 4:00 PM ET

36.38 Day range 37.88
10.41 52-week range 39.97
YTD
+142.26%
1 year
+165.12%
Market cap
2.78B
Revenue (ttm)
200.49M
Profit margin
-58.79%
EPS (ttm)
-1.56
Shares out
75.04M
Forward P/E
-9.85
YTD return
+142.26%
1-year return
+165.12%
Volume
958.16K
Avg volume
1.55M
Open
37.70
Previous close
38.13
Day's range
36.38 – 37.88
52-week range
10.41 – 39.97
Beta
0.77
Analysts
Strong Buy
Price target
42.50 (+14.6%)
Earnings date
Feb 24, 2027

5D +0.64 (+1.76%)

363840MonTueWedThuFri37.09

Key statistics

Enterprise value
2.62B
PEG ratio
0.00
Price / sales
13.88
Price / book
4.95
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
454.90%
Free cash flow
-96.22M
Total cash
405.08M
Total debt
160.23M
Return on equity
-19.88%
Short % of float
24.29%
50-day average
27.13
200-day average
17.98

Fundamental scorecard

6 of 25 checks passed on XNCR’s reported financials

Value: 0/5ValueGrowth: 2/5GrowthProfitability: 1/5ProfitabilityFinancial health: 3/5HealthDividend: 0/5Dividend

6of 25 checks passed

  • Value 0 of 5
  • Growth 2 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
XNCR Revenue — quarterly 116.52M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
XNCR Net income — quarterly 39.44M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
XNCR EPS — quarterly 0.52
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

XNCR recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 24, 2027Dec 30, 2026-0.78544———
Nov 4, 2026Sep 30, 2026-0.334130.50+0.83+249.64%
Aug 5, 2026Jun 30, 2026-0.80145-0.29+0.51+63.82%
May 6, 2026Mar 31, 2026-0.65-1.71-1.06-163.08%
Feb 25, 2026Dec 31, 2025-0.64-0.09+0.55+85.94%
Nov 5, 2025Sep 30, 2025-0.72-0.08+0.64+88.89%

Upgrades / downgrades

XNCR analyst upgrades and downgrades
DateFirmActionFromTo
Nov 5, 2026Cantor FitzgeraldreitOverweightOverweight
Oct 27, 2026Truist SecuritiesmainBuyBuy
Oct 27, 2026RBC CapitalmainOutperformOutperform
Oct 27, 2026Wells FargomainOverweightOverweight
Oct 27, 2026WedbushmainOutperformOutperform
Oct 21, 2026WedbushreitOutperformOutperform

About Xencor, Inc.

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
xencor.com

News

Your note

Sign in to keep a note on XNCR — it syncs with the Stock Master app.

Insider holders

XNCR insider holders
InsiderRelationLatest transactionDateShares held
CORNELISSEN BART JANOfficerSaleNov 10, 202665,798
DAHIYAT BASSIL ISHMAELChief Executive OfficerSaleMar 5, 2026546,316
DESJARLAIS JOHN ROfficerSaleMar 5, 2026263,831
ECKERT CELIA EGeneral CounselSaleMar 5, 202676,918
GUSTAFSON KURT ADirectorStock Award(Grant)Jun 15, 202625,011
KLENCKE BARBARA M.D.DirectorStock Award(Grant)Jun 15, 202629,974

Institution ownership

XNCR institution ownership
Holder% heldSharesValueReported
Blackrock Inc.18.19%13,651,261506.33MJun 29, 2026
Primecap Management Company13.17%9,879,855366.44MSep 29, 2026
BVF Inc.9.51%7,133,720264.59MJun 29, 2026
RTW Investments LP9.03%6,777,461251.38MJun 29, 2026
RA Capital Management, L.P.7.03%5,274,274195.62MJun 29, 2026
State Street Corporation5.54%4,156,734154.17MSep 29, 2026

Fund ownership

XNCR fund ownership
Holder% heldSharesValueReported
PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund8.33%6,249,560231.80MSep 29, 2026
iShares Trust-iShares Core S&P Small-Cap ETF5.42%4,070,592150.98MSep 29, 2026
PRIMECAP Odyssey Funds-PRIMECAP Odyssey Growth Fund3.99%2,993,850111.04MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.12%2,341,98886.86MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.41%1,805,43166.96MSep 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF1.74%1,303,90648.36MSep 29, 2026